Abstract
Antibodies in the blood of a kidney transplant recipient can provide a barrier to transplantation, which is additional to the usual possibility of cellular rejection. The antibodies most frequently encountered are ABO (blood group) and human leucocyte antigen (HLA) (tissue-type) antibodies. About 250 living donor transplants each year in the United Kingdom have been stopped because of an antibody barrier. It is now possible to offer a choice of treatment modalities to these people, including exchange transplantation and antibody-incompatible transplantation. It is likely that both schemes will complement each other and both are available in the United Kingdom.
MeSH terms
-
ABO Blood-Group System / immunology
-
Blood Group Incompatibility / diagnosis
-
Blood Group Incompatibility / immunology
-
Blood Group Incompatibility / prevention & control*
-
Choice Behavior
-
Clinical Protocols
-
Donor Selection / organization & administration
-
Graft Rejection / immunology
-
Graft Rejection / prevention & control
-
Graft Survival
-
HLA Antigens / immunology
-
Health Services Accessibility
-
Health Services Needs and Demand
-
Histocompatibility Testing
-
Humans
-
Kidney Transplantation* / methods
-
Kidney Transplantation* / mortality
-
Kidney Transplantation* / statistics & numerical data
-
Living Donors / statistics & numerical data
-
Patient Selection
-
Plasmapheresis
-
Risk Factors
-
Tissue and Organ Procurement / organization & administration*
-
Treatment Outcome
-
United Kingdom / epidemiology
Substances
-
ABO Blood-Group System
-
HLA Antigens